RESUMEN
OBJECTIVES: To describe and validate an isotope dilution-liquid chromatograph-tandem mass spectrometry (ID-LC-MS/MS) based reference measurement procedure (RMP) for zonisamide to accurately measure serum and plasma concentrations. METHODS: Quantitative nuclear magnetic resonance (qNMR) spectroscopy was employed to determine the absolute content of the reference material used in order to establish traceability to SI units. Separation of zonisamide from known or unknown interferences was performed on a C8 column. For sample preparation a protocol based on protein precipitation in combination with a high dilution step was established. Assay validation and determination of measurement uncertainty were performed based on guidelines from the Clinical and Laboratory Standards Institute, the International Conference on Harmonization, and the Guide to the expression of uncertainty in measurement. RESULTS: The RMP was proven to be highly selective and specific with no evidence of a matrix effect, allowing for quantification of zonisamide within the range of 1.50-60.0⯵g/mL. Intermediate precision was <1.4â¯% and repeatability CV ranged from 0.7 to 1.2â¯% over all concentration levels. The relative mean bias ranged from 0.0 to 0.8â¯% for native serum levels and from 0.2 to 2.0â¯% for Li-heparin plasma levels. The measurement uncertainties for single measurements and target value assignment ranged from 1.1 to 1.4â¯% and 0.8-1.0â¯%, respectively. CONCLUSIONS: We present a novel LC-MS/MS-based candidate RMP for zonisamide in human serum and plasma which provides a traceable and reliable platform for the standardization of routine assays and evaluation of clinically relevant samples.
Asunto(s)
Isoxazoles , Espectrometría de Masas en Tándem , Zonisamida , Humanos , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Zonisamida/sangre , Cromatografía Liquida/métodos , Cromatografía Liquida/normas , Isoxazoles/sangre , Estándares de Referencia , Técnicas de Dilución del Indicador , Análisis Químico de la Sangre/métodos , Análisis Químico de la Sangre/normas , Cromatografía Líquida con Espectrometría de MasasRESUMEN
The poultry red mite (PRM), Dermanyssus gallinae, a potential vector of pathogens to animals and humans, causes impaired bird welfare. A study investigated changes in behavioural variables, physiological biomarkers, and health parameters following acaricidal treatment of PRM infestation of laying hens on a commercial farm. Mite traps determined the challenge to 12,700 hens before and after drinking water administration of the acaricide, fluralaner (Exzolt®, 0.5 mg/kg; Weeks 0 and 1). Weekly daytime direct observations and night-time video recordings monitored bird behaviours from Weeks -6 through +6. Blood samples were collected from randomly-selected birds (Weeks -6, -1, and +6). Following treatment, mite count reductions (>99%) were statistically significant (P < 0.0001), as were night-time reductions in the percent of hens showing activity, preening, head scratching (all P < 0.0001), and head shaking (P = 0.0007). Significant daytime reductions were observed in preening and head scratching (both P < 0.0001), head shaking (P = 0.0389), severe feather pecking (P = 0.0002), and aggressive behaviour (P = 0.0165). Post-treatment, comb wounds were significantly reduced (P = 0.0127), and comb colour was significantly improved (P < 0.0001). Heterophil/lymphocyte ratio was significantly reduced at Weeks 1 and 6 (P = 0.0009 and P < 0.0001, respectively). At Week 6, blood corticosterone (P = 0.0041) and total oxidant status (P < 0.0001) were significantly reduced, and haemoglobin and mean corpuscular haemoglobin significantly increased (P < 0.0001). Farm production records indicated that those post-treatment improvements were accompanied by significant reductions in weekly mortality rate (P = 0.0169), and significant recovery in mean weekly egg weights (P < 0.0001) and laying rate (P < 0.0001). The improvements in behavioural variables, physiological biomarkers, and health parameters that were observed following the elimination of PRM on a commercial farm indicate that infestations can be a cause of reduced hen welfare.
Asunto(s)
Acaricidas/sangre , Isoxazoles/sangre , Enfermedades de las Aves de Corral/tratamiento farmacológico , Aves de Corral/parasitología , Ácaros y Garrapatas/efectos de los fármacos , Ácaros y Garrapatas/patogenicidad , Acaricidas/administración & dosificación , Acaricidas/farmacología , Acaricidas/uso terapéutico , Animales , Conducta Animal , Femenino , Hemoglobinas/análisis , Isoxazoles/administración & dosificación , Isoxazoles/farmacología , Isoxazoles/uso terapéutico , Recuento de Linfocitos , Reproducción/efectos de los fármacosRESUMEN
BACKGROUND: The present study aimed to develop and validate a rapid, selective, and reproducible ultra-performance liquid chromatography-tandem mass spectrometry separation method for the simultaneous determination of the levels of parecoxib and its main metabolite valdecoxib in rat plasma. Moreover, this method was applied to investigate the pharmacokinetics of parecoxib and valdecoxib in rats. METHODS: Following the addition of celecoxib as an internal standard, one-step protein precipitation by acetonitrile was used for sample preparation. The effective chromatographic separation was carried out using an ACQUITY UPLC®BEH C18 reversed phase column (2.1 mm × 50 mm, 1.7 µm particle size) with acetonitrile and water (containing 0.1% formic acid) as the mobile phase. The procedure was performed in less than 3 min with a gradient elution pumped at a flow rate of 0.4 ml/min. The electrospray ionization source was applied and operated in the positive ion mode and multiple reaction monitoring mode was used for quantification using the following: target fragment ions: m/z 371 â 234 for parecoxib, m/z 315 â 132 for valdecoxib and m/z 382 â 362 for celecoxib. RESULTS: The method validation demonstrated optimal linearity over the range of 50-10,000 ng/ml (r2 ≥ 0.9996) and 2.5-500 ng/ml (r2 ≥ 0.9991) for parecoxib and valdecoxib in rat plasma, respectively. CONCLUSIONS: The present study demonstrated a simple, sensitive and applicable method for the quantification of parecoxib and its main pharmacologically active metabolite valdecoxib following sublingual vein administration of 5 mg/kg parecoxib in rats.
Asunto(s)
Inhibidores de la Ciclooxigenasa 2/sangre , Isoxazoles/sangre , Sulfonamidas/sangre , Animales , Cromatografía Líquida de Alta Presión/métodos , Inhibidores de la Ciclooxigenasa 2/farmacocinética , Isoxazoles/farmacocinética , Masculino , Ratas Sprague-Dawley , Sulfonamidas/farmacocinética , Espectrometría de Masas en TándemRESUMEN
A method for the simultaneous determination of parecoxib and its metabolite valdecoxib in beagle plasma by UPLC-MS/MS was developed and validated. After the plasma was extracted by acetonitrile precipitation, the analytes were separated on an Acquity UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 µm) using acetonitrile-formic acid as the mobile phase in gradient mode. The analytes were monitored by multiple reaction monitoring (MRM) in electrospray negative ion mode. The mass transfer pairs were m/z 368.97â119.01 for parecoxib, m/z 312.89â118.02 for valdecoxib, and m/z 379.98â316.02 for celecoxib (internal standard, IS). The correlation coefficients of parecoxib and valdecoxib ranged from 5 to 4000 ng/mL were greater than 0.9998. The recovery of parecoxib and valdecoxib was greater than 82.54%. The inter- and intra-day precision RSD values were 1.36~3.65% and 2.28~5.91%, respectively. The accuracy of RE values were -1.38%~1.96%. Finally, the matrix effect (ME) and stability were also within acceptable criteria. This method had been successfully applied to the pharmacokinetics of parecoxib and valdecoxib in beagle plasma after injection of parecoxib (1.33 mg/kg, intramuscular injection).
Asunto(s)
Isoxazoles/sangre , Isoxazoles/metabolismo , Sulfonamidas/sangre , Sulfonamidas/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Perros , Inyecciones Intramusculares , Isoxazoles/administración & dosificación , Isoxazoles/farmacocinética , Estructura Molecular , Sulfonamidas/administración & dosificación , Sulfonamidas/farmacocinética , Espectrometría de Masas en TándemRESUMEN
Endothelin receptor antagonists (ERAs) such as, ambrisentan, macitentan and sitaxentan are primarily used for the treatment of pulmonary arterial hypertension. Considering the rise in endothelin in pre-eclampsia, ERAs may also be useful in its treatment. To evaluate the pharmacokinetics of ERAs, a rapid ultra-performance liquid chromatography tandem mass spectrometry method was developed and validated to determine the concentration of ambrisentan, macitentan and sitaxentan in human plasma. Plasma samples were treated with methanol to induce protein precipitation. A chromatographic separation was performed on a C18 column using a gradient of methanol-water containing 0.1% formic acid and 0.013% ammonium acetate and a flow rate of 0.5 ml/min. Multiple reaction monitoring was used for quantification. This method was validated in a linear range of 20.28-2028 µg/l for ambrisentan, 4.052-405.2 µg/l for macitentan and 205.4-10 270 µg/l for sitaxentan. The method was successfully validated according to US Food and Drug Administration guidelines to determine the concentrations of macitentan, ambrisentan and sitaxentan in human plasma. This method is now being used for study samples and clinical patient samples.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Isoxazoles/sangre , Fenilpropionatos/sangre , Piridazinas/sangre , Pirimidinas/sangre , Sulfonamidas/sangre , Espectrometría de Masas en Tándem/métodos , Tiofenos/sangre , Antihipertensivos/sangre , Antihipertensivos/química , Humanos , Isoxazoles/química , Modelos Lineales , Fenilpropionatos/química , Piridazinas/química , Pirimidinas/química , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Sulfonamidas/química , Tiofenos/químicaRESUMEN
There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. We evaluated the in vitro activity of MGX and the efficacy of the prodrug fosmanogepix (APX001) in immunosuppressed murine models of hematogenously disseminated fusariosis and pulmonary scedosporiosis. The MGX minimum effective concentration (MEC) for Scedosporium isolates was 0.03 µg/ml and ranged from 0.015 to 0.03 µg/ml for Fusarium isolates. In the scedosporiosis model, treatment of mice with 78 mg/kg and 104 mg/kg of body weight fosmanogepix, along with 1-aminobenzotriazole (ABT) to enhance the serum half-life of MGX, significantly increased median survival time versus placebo from 7 days to 13 and 11 days, respectively. Furthermore, administration of 104 mg/kg fosmanogepix resulted in an â¼2-log10 reduction in lung, kidney, or brain conidial equivalents/gram tissue (CE). Similarly, in the fusariosis model, 78 mg/kg and 104 mg/kg fosmanogepix plus ABT enhanced median survival time from 7 days to 12 and 10 days, respectively. A 2- to 3-log10 reduction in kidney and brain CE was observed. In both models, reduction in tissue fungal burden was corroborated with histopathological data, with target organs showing reduced or no abscesses in fosmanogepix-treated mice. Survival and tissue clearance were comparable to a clinically relevant high dose of liposomal amphotericin B (10 to 15 mg/kg). Our data support the continued development of fosmanogepix as a first-in-class treatment for infections caused by these rare molds.
Asunto(s)
Aminopiridinas/farmacología , Antifúngicos/farmacología , Fusariosis/tratamiento farmacológico , Fusarium/efectos de los fármacos , Huésped Inmunocomprometido , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Isoxazoles/farmacología , Scedosporium/efectos de los fármacos , Aminopiridinas/sangre , Aminopiridinas/farmacocinética , Animales , Antifúngicos/sangre , Antifúngicos/farmacocinética , Disponibilidad Biológica , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Encéfalo/microbiología , Esquema de Medicación , Combinación de Medicamentos , Fusariosis/inmunología , Fusariosis/microbiología , Fusariosis/mortalidad , Fusarium/crecimiento & desarrollo , Fusarium/inmunología , Semivida , Humanos , Infecciones Fúngicas Invasoras/inmunología , Infecciones Fúngicas Invasoras/microbiología , Infecciones Fúngicas Invasoras/mortalidad , Isoxazoles/sangre , Isoxazoles/farmacocinética , Riñón/efectos de los fármacos , Riñón/inmunología , Riñón/microbiología , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/microbiología , Masculino , Ratones , Ratones Endogámicos ICR , Pruebas de Sensibilidad Microbiana , Profármacos , Scedosporium/crecimiento & desarrollo , Scedosporium/inmunología , Análisis de Supervivencia , Triazoles/farmacologíaRESUMEN
Cognitive impairments are a common consequence of traumatic brain injury (TBI). The hippocampus is a subcortical structure that plays a key role in the formation of declarative memories and is highly vulnerable to TBI. The α7 nicotinic acetylcholine receptor (nAChR) is highly expressed in the hippocampus and reduced expression and function of this receptor are linked with cognitive impairments in Alzheimer's disease and schizophrenia. Positive allosteric modulation of α7 nAChRs with AVL-3288 enhances receptor currents and improves cognitive functioning in naïve animals and healthy human subjects. Therefore, we hypothesized that targeting the α7 nAChR with the positive allosteric modulator AVL-3288 would enhance cognitive functioning in the chronic recovery period of TBI. To test this hypothesis, adult male Sprague Dawley rats received moderate parasagittal fluid-percussion brain injury or sham surgery. At 3 months after recovery, animals were treated with vehicle or AVL-3288 at 30 min prior to cue and contextual fear conditioning and the water maze task. Treatment of TBI animals with AVL-3288 rescued learning and memory deficits in water maze retention and working memory. AVL-3288 treatment also improved cue and contextual fear memory when tested at 24 hr and 1 month after training, when TBI animals were treated acutely just during fear conditioning at 3 months post-TBI. Hippocampal atrophy but not cortical atrophy was reduced with AVL-3288 treatment in the chronic recovery phase of TBI. AVL-3288 application to acute hippocampal slices from animals at 3 months after TBI rescued basal synaptic transmission deficits and long-term potentiation (LTP) in area CA1. Our results demonstrate that AVL-3288 improves hippocampal synaptic plasticity, and learning and memory performance after TBI in the chronic recovery period. Enhancing cholinergic transmission through positive allosteric modulation of the α7 nAChR may be a novel therapeutic to improve cognition after TBI.
Asunto(s)
Lesiones Traumáticas del Encéfalo/complicaciones , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/etiología , Receptor Nicotínico de Acetilcolina alfa 7/metabolismo , Regulación Alostérica/efectos de los fármacos , Anilidas/sangre , Anilidas/farmacocinética , Anilidas/farmacología , Anilidas/uso terapéutico , Animales , Atrofia , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Enfermedad Crónica , Trastornos del Conocimiento/fisiopatología , Condicionamiento Clásico , Miedo , Isoxazoles/sangre , Isoxazoles/farmacocinética , Isoxazoles/farmacología , Isoxazoles/uso terapéutico , Potenciación a Largo Plazo/efectos de los fármacos , Masculino , Aprendizaje por Laberinto , Memoria a Corto Plazo , Ratas Sprague-Dawley , Transmisión Sináptica/efectos de los fármacosRESUMEN
Excessive mitochondrial matrix Ca2+ and oxidative stress leads to the opening of a high-conductance channel of the inner mitochondrial membrane referred to as the mitochondrial permeability transition pore (mtPTP). Because mtPTP opening can lead to cell death under diverse pathophysiological conditions, inhibitors of mtPTP are potential therapeutics for various human diseases. High throughput screening efforts led to the identification of a 3-carboxamide-5-phenol-isoxazole compounds as mtPTP inhibitors. While they showed nanomolar potency against mtPTP, they exhibited poor plasma stability, precluding their use in inâ vivo studies. Herein, we describe a series of structurally related analogues in which the core isoxazole was replaced with a triazole, which resulted in an improvement in plasma stability. These analogues were readily generated using the copper-catalyzed "click chemistry". One analogue, N-(5-chloro-2-methylphenyl)-1-(4-fluoro-3-hydroxyphenyl)-1H-1,2,3-triazole-4-carboxamide (TR001), was efficacious in a zebrafish model of muscular dystrophy that results from mtPTP dysfunction whereas the isoxazole isostere had minimal effect.
Asunto(s)
Isoxazoles/farmacología , Proteínas de Transporte de Membrana Mitocondrial/antagonistas & inhibidores , Distrofias Musculares/tratamiento farmacológico , Fenoles/farmacología , Animales , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Células HeLa , Ensayos Analíticos de Alto Rendimiento , Humanos , Isoxazoles/sangre , Isoxazoles/química , Proteínas de Transporte de Membrana Mitocondrial/metabolismo , Poro de Transición de la Permeabilidad Mitocondrial , Estructura Molecular , Distrofias Musculares/metabolismo , Fenoles/sangre , Fenoles/química , Relación Estructura-Actividad , Células Tumorales Cultivadas , Pez CebraRESUMEN
The aim of the present study was to compare the effect of oral and subcutaneous exposure to a glyphosate-based herbicide (GBH) on the female reproductive system, specifically in the ovaries and uterus of prepubertal lambs. To this end, ewe lambs were exposed to a s.c. (n: 5) or an oral (n: 5) environmentally relevant dose of GBH (2â¯mg/kg/day) or to vehicle (controls, n: 12), from postnatal day (PND) 1 to PND14. Serum glyphosate and aminomethylphosphonic acid (AMPA) concentrations were measured on PND15 and PND45. The ovaries and uterus were obtained and weighed on PND45. Ovarian follicular dynamics and uterine morphological features were determined by picrosirius-hematoxylin staining. The proliferation marker Ki67 was evaluated by immunohistochemistry in ovarian and uterine samples. Glyphosate but not AMPA was detected in serum of exposed lambs on PND15, whereas neither glyphosate nor AMPA were detected on PND45. Controls were negative for glyphosate and AMPA on PND15 and PND45. GBH exposure did not affect ovarian or uterine weight. However, on PND45, the ovary of GBH-exposed lambs showed altered follicular dynamics, increased proliferation of granulosa and theca cells, and decreased mRNA expression of FSHR and GDF9, whereas their uterus showed decreased cell proliferation but no alterations in the histomorphology or gene expression. In conclusion, GBH exposure altered the ovarian follicular dynamics and gene expression, and the proliferative activity of the ovaries and uterus of lambs. It is noteworthy that all the adverse effects found in the ovaries and uterus of both GBH-exposed groups were similar, independently of the administration route.
Asunto(s)
Glicina/análogos & derivados , Herbicidas/efectos adversos , Ovario/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Útero/efectos de los fármacos , Administración Oral , Animales , Animales Recién Nacidos , Proliferación Celular , Femenino , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Glicina/efectos adversos , Glicina/sangre , Glicina/farmacología , Factor 9 de Diferenciación de Crecimiento/genética , Herbicidas/sangre , Herbicidas/farmacología , Inyecciones Subcutáneas , Isoxazoles/sangre , Tamaño de los Órganos/efectos de los fármacos , Ovario/citología , Ovario/metabolismo , Embarazo , Efectos Tardíos de la Exposición Prenatal/sangre , Efectos Tardíos de la Exposición Prenatal/genética , Receptores de HFE/genética , Oveja Doméstica , Tetrazoles/sangre , Útero/citología , Útero/metabolismo , GlifosatoRESUMEN
Overexpression of Cyclooxygenase-2 (COX-2) enzyme is associated with the pathogenesis of inflammation, cancers, stroke, arthritis, and neurological disorders. Because of the involvement of COX-2 in these diseases, quantification of COX-2 expression using Positron Emission Tomography (PET) may be a biological marker for early diagnosis, monitoring of disease progression, and an indicator of effective treatment. At present there is no target-specific or validated PET tracer available for in vivo quantification of COX-2. The objective of this study is to evaluate [11C]TMI, a selective COX-2 inhibitor (Kiâ¯≤â¯1â¯nM) in nonhuman primates using PET imaging. PET imaging in baboons showed that [11C]TMI penetrates the blood brain barrier (BBB) and accumulates in brain in a somewhat heterogeneous pattern. Metabolite analyses indicated that [11C]TMI undergoes no significant metabolism of parent tracer in the plasma for baseline scans, however a relative faster metabolism was found for blocking scan. All the tested quantification approaches provide comparable tracer total distribution volume (VT) estimates in the range of 3.2-7â¯(mL/cm3). We observed about 25% lower VT values in blocking studies with meloxicam, a nonselective COX-2 inhibitor, compared to baseline [11C]TMI binding. Our findings indicate that [11C]TMI may be a suitable PET tracer for the quantification of COX-2 in vivo. Further experiments are needed to confirm the potential of this tracer in COX-2 overexpressing models for brain diseases.
Asunto(s)
Ciclooxigenasa 2/metabolismo , Isoxazoles/química , Radiofármacos/química , Sulfonas/química , Animales , Barrera Hematoencefálica/metabolismo , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Radioisótopos de Carbono/química , Inhibidores de la Ciclooxigenasa 2/sangre , Inhibidores de la Ciclooxigenasa 2/química , Inhibidores de la Ciclooxigenasa 2/metabolismo , Isoxazoles/sangre , Isoxazoles/metabolismo , Papio , Tomografía de Emisión de Positrones , Radiofármacos/sangre , Radiofármacos/metabolismo , Sulfonas/sangre , Sulfonas/metabolismoRESUMEN
BACKGROUND: CredelioTM (lotilaner) is an oral ectoparasiticide from the isoxazoline class developed for the treatment of flea and tick infestations in cats. It is formulated as a pure S-enantiomer in flavoured chewable tablets. The pharmacokinetics of lotilaner were investigated after intravenous or oral administration and under fed or fasted conditions in cats. Twenty-six adult cats were enrolled in a pharmacokinetic study evaluating either intravenous or oral administration of lotilaner. Following the oral administration at a dosage of 6 mg/kg, under fed or fasted conditions, or intravenous administration of 3 mg/kg, blood samples were collected up to 35 days after treatment. Lotilaner blood concentrations were measured using a validated liquid chromatography/tandem mass spectrometry method. Pharmacokinetic parameters were calculated by non-compartmental analysis. In addition, in vivo enantiomer stability of lotilaner was evaluated in a separate bioanalytical study. RESULTS: Following oral administration in fed cats, lotilaner was readily absorbed and peak blood concentrations reached within four hours. The terminal half-life was 33.6 days. Food enhanced the absorption, providing close to 100% oral bioavailability and reduced the inter-individual variability. Following intravenous administration, lotilaner had a low clearance of 0.13 l/kg/day, large volumes of distribution Vz and Vss of 5.34 and 5.37 l/kg, respectively and a terminal half-life of 28.7 days. In addition, there was no in vivo racemization of lotilaner. CONCLUSIONS: The pharmacokinetic properties of lotilaner administered orally as a flavoured chewable tablet (CredelioTM) were studied in detail. With a Tmax of 4 h and a terminal half-life of 33.6 days under fed conditions, lotilaner provides a rapid onset of flea and tick killing activity with consistent and sustained efficacy for at least one month in cats.
Asunto(s)
Acaricidas/administración & dosificación , Acaricidas/farmacocinética , Isoxazoles/administración & dosificación , Isoxazoles/farmacocinética , Acaricidas/sangre , Administración Intravenosa , Administración Oral , Animales , Disponibilidad Biológica , Gatos , Dieta , Femenino , Semivida , Isoxazoles/sangre , MasculinoRESUMEN
A sensitive, selective rapid bioanalytical assay method was developed and quantification of iloperidone (ILP) and olanzapine (OLZ) in rat plasma was done by mass spectrometry. Systematic sample preparation and extraction procedure were carried out by supported liquid extraction using dichloromethane to extract both the eluents (ILP and OLZ) from rat plasma samples. The extorted samples were injected on a selective Waters XTerra® C18 reverse-phase bonded column (250 × 4.6 mm i.d., 5 µm) using acetonitrile and 15 mM ammonium formate containing 0.05% trifluoroacetic acid (60:40 v/v) for isocratic elution mode and detected by mass spectrometry. Calibration curves were drawn with the respective assay statistical data and showed linear regression coefficients greater than 0.9996 over the concentration ranges 2-5,000 ng/mL for ILP and OLZ, respectively. The absolute mean recoveries were found to be in the replicate range of 87.12-94.47%, respectively. The obtained results by the method revealed good intra and interday assay performance in terms of 1.70-5.90% precision and 0-5% accuracy. The validated bioassay method has been successfully applied to the pharmacokinetics in rats.
Asunto(s)
Cromatografía Liquida/métodos , Isoxazoles/sangre , Olanzapina/sangre , Piperidinas/sangre , Espectrometría de Masas en Tándem/métodos , Animales , Isoxazoles/farmacocinética , Límite de Detección , Modelos Lineales , Masculino , Olanzapina/farmacocinética , Piperidinas/farmacocinética , Ratas , Ratas Wistar , Reproducibilidad de los ResultadosRESUMEN
A chromatographic method has been developed and validated for the first time for analysis of terizidone in plasma. Terizidone was extracted from plasma by protein precipitation using a mixture of acetonitrile and methanol (1:1, v/v). The chromatographic separation was achieved with a gradient of acetonitrile and water both containing 0.1% formic acid on a Supelco Discovery® HS C18 (150 × 4.6 mm, 5 µm) reversed-phase column. Propranolol was used as the internal standard. The total run-time was 18 min. The calibration standard concentrations ranged between 3.125 and 200 µg/mL and calibration curves were linear with coefficient of determination values in the range of 0.9988-0.9999. The inter- and intra-day assay precision (percentage relative standard error) was <15% while mean accuracy was 107%. The mean extraction efficiencies of terizidone and IS were 76 and 89%, respectively. The validation results demonstrated that the method was selective and sensitive, and that terizidone was stable under the studied conditions. The method was successfully applied in a population pharmacokinetic study. The mean plasma concentration of terizidone in patients at all sampling time points was 51.8 ± 28 µg/mL. The method was simple, cheap and hence suitable for therapeutic drug monitoring of terizidone.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Isoxazoles/sangre , Oxazolidinonas/sangre , Espectrometría de Masas en Tándem/métodos , Humanos , Isoxazoles/farmacocinética , Límite de Detección , Modelos Lineales , Oxazolidinonas/farmacocinética , Reproducibilidad de los ResultadosRESUMEN
Glyphosate-based herbicides (GBHs) are the most globally used herbicides raising the risk of environmental exposition. Here, we investigated whether perinatal exposure to low doses of a GBH alters the female reproductive performance, and/or induced second-generation effects related to congenital anomalies or growth alterations. Pregnant rats (F0) received a GBH through food, in a dose of 2 mg (GBH-LD: GBH-low dose group) or 200 mg (GBH-HD: GBH-high dose group) of glyphosate/kg bw/day from gestational day (GD) 9 until weaning. Body weight gain and vaginal canal-opening of F1 females were recorded. Sexually mature F1 females were mated to evaluate their reproductive performance by assessing the pregnancy rate, and on GD19, the number of corpora lutea, the implantation sites (IS) and resorption sites. To analyze second-generation effects on F2 offspring, we analyzed the fetal morphology on GD19, and assessed the fetal length and weight, and the placental weight. GBH exposure neither altered the body weight gain of F1 females, nor vaginal opening onset. Although all GBH-exposed F1 rats became pregnant, a lower number of IS was detected. F2 offspring from both GBH groups showed delayed growth, evidenced by lower fetal weight and length, associated with a higher incidence of small for gestational age fetuses. In addition, higher placental weight and placental index were found in F2 offspring from GBH-HD dams. Surprisingly, structural congenital anomalies (conjoined fetuses and abnormally developed limbs) were detected in the F2 offspring from GBH-HD group. In conclusion, perinatal exposure to low doses of a GBH impaired female reproductive performance and induced fetal growth retardation and structural congenital anomalies in F2 offspring.
Asunto(s)
Glicina/análogos & derivados , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Reproducción/efectos de los fármacos , Animales , Peso Corporal/efectos de los fármacos , Femenino , Retardo del Crecimiento Fetal/inducido químicamente , Glicina/administración & dosificación , Glicina/toxicidad , Herbicidas/toxicidad , Isoxazoles/sangre , Lactancia , Masculino , Placenta/efectos de los fármacos , Placenta/patología , Embarazo , Índice de Embarazo , Pubertad/efectos de los fármacos , Pubertad/fisiología , Ratas Wistar , Reproducción/fisiología , Tetrazoles/sangre , GlifosatoRESUMEN
Hsp90 inhibitors, well studied in the laboratory and clinic for antitumor indications, have promising activity against protozoan pathogens, including Trypanosoma brucei which causes African sleeping sickness, and the malaria parasite, Plasmodium falciparum To progress these experimental drugs toward clinical use, we adapted an in vitro dynamic hollow-fiber system and deployed artificial pharmacokinetics to discover the driver of their activity: either concentration or time. The activities of compounds from three major classes of Hsp90 inhibitors in development were evaluated against trypanosomes. In all circumstances, the activities of the tested Hsp90 inhibitors were concentration driven. By optimally deploying the drug to match its kinetic driver, the efficacy of a given dose was improved up to 5-fold, and maximal efficacy was achieved with a significantly lower drug exposure. The superiority of concentration-driven regimens was evident in vitro over several logs of drug exposure and was predictive of efficacy in a mouse model of African trypanosomiasis. In studies with P. falciparum, antimalarial activity was similarly concentration driven. This experimental strategy offers an expedient and versatile translational tool to assess the impact of pharmacokinetics on antiprotozoal activity. Knowing kinetic governance early in drug development provides an additional metric for judging lead compounds and allows the incisive design of animal efficacy studies.
Asunto(s)
Antiprotozoarios/farmacocinética , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Proteínas Protozoarias/antagonistas & inhibidores , Trypanosoma brucei brucei/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológico , Animales , Antineoplásicos/sangre , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Antiprotozoarios/sangre , Antiprotozoarios/farmacología , Área Bajo la Curva , Benzodioxoles/sangre , Benzodioxoles/farmacocinética , Benzodioxoles/farmacología , Benzoquinonas/sangre , Benzoquinonas/farmacocinética , Benzoquinonas/farmacología , Bioensayo , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Femenino , Expresión Génica , Proteínas HSP90 de Choque Térmico/genética , Proteínas HSP90 de Choque Térmico/metabolismo , Imidazoles/sangre , Imidazoles/farmacocinética , Imidazoles/farmacología , Isoxazoles/sangre , Isoxazoles/farmacocinética , Isoxazoles/farmacología , Lactamas Macrocíclicas/sangre , Lactamas Macrocíclicas/farmacocinética , Lactamas Macrocíclicas/farmacología , Malaria Falciparum/parasitología , Ratones , Modelos Biológicos , Plasmodium falciparum/crecimiento & desarrollo , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Resorcinoles/sangre , Resorcinoles/farmacocinética , Resorcinoles/farmacología , Trypanosoma brucei brucei/crecimiento & desarrollo , Tripanosomiasis Africana/parasitologíaRESUMEN
Parecoxib (PX), a prodrug of valdecoxib (VX), is an injectable selective COX-2 inhibitor, and is recommended for the treatment of cancer pain. PX can be rapidly hydrolyzed into its active metabolite VX, and VX is further metabolized into hydroxylated valdecoxib (OH-VX) by cytochrome P450 enzymes. However, cancer patients have been reported to possess reduced drug metabolism ability, which might cause excessive drug accumulation. Such overdose of PX significantly increased the risk of renal safety and cardiovascular events. Therefore, it is necessary to elucidate the concentration profiles of PX and its metabolites in cancer status. In this study, a sensitive, rapid and specific LC-MS/MS method for quantification of PX, VX and OH-VX in the plasma of tumor bearing mouse was developed and validated. After protein precipitation, all the analytes were separated on an Agilent ZORBAX Extend-C18 HPLC column (2.1â¯×â¯100â¯mm, 3.5⯵m) with gradient elution. The analytes were detected by an electrospray negative ionization mass spectrometry in the multiple reaction monitoring mode. The transition m/z 369.0â¯ââ¯119.0,â¯m/z 312.9â¯ââ¯117.9, m/z 329.0â¯ââ¯196.0, and m/z 307.1â¯ââ¯161.3 were used for monitoring PX, VX, OH-VX and IS respectively. The calibration curves of the analytes showed good linearity over the concentration range of 3-3000â¯ng/mL for PX and VX, and 3-1000â¯ng/mL for OH-VX. Intra- and inter-batch accuracies (in terms of relative error, REâ¯<â¯9.9%) and precisions (in terms of relative standard deviation, RSDâ¯<â¯8.8%) satisfied the standard of validation. The matrix effect, recovery and stability were also within acceptable criteria. The method was successfully applied to the pharmacokinetics study of PX in tumor bearing mice, and PX and VX levels were found elevated with the growth of tumor volume, which might increase the risk of drug overdose.
Asunto(s)
Inhibidores de la Ciclooxigenasa 2/sangre , Monitoreo de Drogas/métodos , Isoxazoles/sangre , Neoplasias/metabolismo , Profármacos/análisis , Animales , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Inhibidores de la Ciclooxigenasa 2/metabolismo , Sistema Enzimático del Citocromo P-450/metabolismo , Monitoreo de Drogas/instrumentación , Femenino , Humanos , Isoxazoles/metabolismo , Isoxazoles/farmacocinética , Ratones , Ratones Endogámicos BALB C , Neoplasias/sangre , Oxazoles/sangre , Oxazoles/metabolismo , Oxazoles/farmacocinética , Profármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray , Sulfonamidas/sangre , Sulfonamidas/metabolismo , Sulfonamidas/farmacocinética , Espectrometría de Masas en Tándem/instrumentación , Espectrometría de Masas en Tándem/métodos , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: Zoonotic visceral leishmaniasis (ZVL) caused by Leishmania (Leishmania) infantum is an important disease in humans and dogs. Different mammal species are reservoirs but dogs are considered to be the main one. Phlebotomine sand flies are the proven vector. Four systemic insecticides approved for their use in dogs were previously selected based on their potential to be used in endemic countries as part of the control programs of ZVL. These insecticides are proved to be safe and effective against the on-label insects and parasites, but there is no information about their activity against phlebotomine sand flies. METHODS: The phlebotomine mortality of four systemic insecticides in dogs was evaluated using two randomized clinical trials. For the first trial, thirty dogs were randomly allocated into five groups: four treatments and one control, of equal size. The treatments evaluated were: Guardian®SR, Elanco (moxidectin); Comfortis®, Elanco (spinosad); Bravecto®, Merck Animal Health (fluralaner); and NexGard®, Merial (afoxolaner). Blood from dogs was taken at days 2, 4, 21 and 31 post-treatment (trial 1). The compound that showed the highest efficacy was selected for a second trial (trial 2) with 20 dogs sampled at days 0, 2, 4, 7, 14, 18, 32, 39, 51 and 84 post-treatment. Membrane feeding bioassays with Phlebotomus papatasi were used to evaluate the phlebotomine mortality efficacy of the different treatments. Phlebotomine mortality was observed every 24 h following the membrane feeding during 5 days. A mixed model for a negative binomial logistic regression, and a Cox proportional hazard mixed model were used to estimate phlebotomine mortality due to different treatments. RESULTS: Fluralaner was the only compound that showed significant phlebotomine mortality. Fluralaner maintained the phlebotomine mortality between 60-80% for 30 days after treatment. In trial 1 we found that fluralaner increased the risk of death by 1.9 times (95% CI: 1.02-3.6) and 1.7 times (95% CI: 1.09-2.6) at days 2 and 4 after treatment. The Cox model resulted in an increase of 1.47 (95% CI: 1.1-1.96) times in hazard risk at day 2 and 1.89 (95% CI: 1.35-2.45) at day 4 after treatment. In trial 2 we found that fluralaner increased the risk of death by 1.64 times (95% CI: 1.16-2.54) and 1.97 times (95% CI: 1.23-3.17) at days 14 and 32. The hazard risk was also increased by 1.92 (95% CI: 1.4-2.64) times at day 14 after treatment. Phlebotomine survival including all experimental days was significantly lower in the fluralaner group in both trials. CONCLUSIONS: A single oral treatment of fluralaner in dogs induces phlebotomine mortality. Systemic insecticides in dogs should be considered as a potential preventive measure of ZVL.
Asunto(s)
Insecticidas , Leishmaniasis Visceral , Phlebotomus , Animales , Perros , Femenino , Masculino , Absorción Fisiológica , Vectores de Enfermedades , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/prevención & control , Combinación de Medicamentos , Insecticidas/administración & dosificación , Insecticidas/sangre , Insecticidas/química , Insecticidas/uso terapéutico , Isoxazoles/administración & dosificación , Isoxazoles/sangre , Isoxazoles/uso terapéutico , Leishmania infantum/fisiología , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/parasitología , Leishmaniasis Visceral/prevención & control , Leishmaniasis Visceral/veterinaria , Macrólidos/administración & dosificación , Macrólidos/sangre , Macrólidos/uso terapéutico , Naftalenos/administración & dosificación , Naftalenos/sangre , Naftalenos/uso terapéutico , Phlebotomus/efectos de los fármacos , Phlebotomus/parasitologíaRESUMEN
AIM: To implement pharmacokinetic drug monitoring and individualize the posology of new antiepileptic drugs, the first HPLC-diode array detection method was developed and validated to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. MATERIALS & METHODS: Preceded by a reproducible liquid-liquid extraction, chromatographic separation was achieved by using a C18 column of 5 cm length and a mobile phase of water/acetonitrile. Full validation was performed according to international guidelines. RESULTS: The method was linear within 0.5-30, 2.5-40.0 and 0.5-50.0 µg ml-1 for lacosamide, levetiracetam and zonisamide, respectively (r2 ≥ 0.998), accurate (-12.411-8.303%), precise (≤8.875%). CONCLUSION: This innovative HPLC-diode array detection method was successfully employed in clinical practice and is expected to empower epileptic patients with a personalized pharmacotherapy service. [Formula: see text].
Asunto(s)
Acetamidas/sangre , Anticonvulsivantes/sangre , Monitoreo de Drogas/métodos , Isoxazoles/sangre , Piracetam/análogos & derivados , Cromatografía Líquida de Alta Presión/métodos , Humanos , Lacosamida , Levetiracetam , Piracetam/sangre , ZonisamidaRESUMEN
INTRODUCTION: Zonisamide is a new-generation anticonvulsant antiepileptic drug metabolized primarily in the liver, with subsequent elimination via the renal route. OBJECTIVES: Our objective was to evaluate the utility of pharmacometabolomics in the detection of zonisamide metabolites that could be related to its disposition and therefore, to its efficacy and toxicity. METHODS: This study was nested to a bioequivalence clinical trial with 28 healthy volunteers. Each participant received a single dose of zonisamide on two separate occasions (period 1 and period 2), with a washout period between them. Blood samples of zonisamide were obtained from all patients at baseline for each period, before volunteers were administered any medication, for metabolomics analysis. RESULTS: After a Lasso regression was applied, age, height, branched-chain amino acids, steroids, triacylglycerols, diacyl glycerophosphoethanolamine, glycerophospholipids susceptible to methylation, phosphatidylcholines with 20:4 FA (arachidonic acid) and cholesterol ester and lysophosphatidylcholine were obtained in both periods. CONCLUSION: To our knowledge, this is the only research study to date that has attempted to link basal metabolomic status with pharmacokinetic parameters of zonisamide.
Asunto(s)
Metabolómica/métodos , Zonisamida/metabolismo , Zonisamida/farmacocinética , Adulto , Anticonvulsivantes/sangre , Anticonvulsivantes/metabolismo , Área Bajo la Curva , Femenino , Voluntarios Sanos , Humanos , Isoxazoles/sangre , Masculino , Fenómenos Farmacológicos/fisiología , Equivalencia Terapéutica , Adulto JovenRESUMEN
BACKGROUND: Poultry mites are the most significant pest affecting production systems in the egg-laying industry. Fluralaner is a novel systemic insecticide and acaricide that is effective against poultry mites (Dermanyssus gallinae, Ornithonyssus sylviarum) in chickens after oral administration. This study investigated the safety of oral administration of a 1% solution of fluralaner in drinking water to laying hens at the recommended treatment dose and at multiples of this dose. METHODS: One hundred-twenty healthy 28-week-old laying hens, weighing 1.4-2.1 kg at first administration, were included in the study, and allocated to 4 treatment groups of 30 hens each receiving daily doses of 0, 0.5, 1.5 and 2.5 mg fluralaner/kg body weight, equivalent to 0, 1, 3, and 5 times the recommended dose of fluralaner. The product was administered via drinking water on a total of six occasions, as 3-day treatment periods twice with an interval of 4 days with no treatment (treatment on days 1, 2, 3 and 8, 9, 10), representing 3 times the recommended number of administrations. Hens supplied with non-medicated drinking water served as controls. During the study, all hens were clinically observed, and their health was carefully monitored including body weight, food and water consumption, hematology, clinical chemistry, and withdrawal reflex test. Eggs laid over the study were evaluated for main characteristics (e.g. weight, shape, strength, shell thickness and soundness, albumen height, yolk color, Haugh unit and presence of blood and/or meat spots). Following euthanasia of the hens at the end of the second treatment period (day 11) or 18 days later (day 29), complete gross post-mortem examination, including organ weight determination, and histopathological examination of multiple tissues were conducted. RESULTS: There were no clinical findings related to fluralaner treatment. Statistically significant differences between the treated groups and the control group were observed for some clinical pathology parameters; none of these findings were considered to be of clinical nor zootechnical relevance. Organ weights, gross post mortem and histopathological examinations did not reveal any finding associated with treatment with fluralaner. CONCLUSIONS: Oral administration of fluralaner via drinking water at the recommended treatment dose (0.5 mg/kg body weight twice at 1-week interval), is well tolerated and has a high safety margin up to an overall dose of 15 times the recommended one (5 times the daily dose given 3 times the number of days) in healthy adult laying hens. Based on the present results, the use of the new mite treatment based on fluralaner administered via drinking water is expected to be safe for laying hens under industrial conditions, and to have no negative impact on their egg quality and production.